

Elizabeth M Oliva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1589640/publications.pdf>

Version: 2024-02-01

32
papers

1,004
citations

516710

16
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

1029
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of a Predictive Analytics-Targeted Program in Patients on Opioids: a Stepped-Wedge Cluster Randomized Controlled Trial. <i>Journal of General Internal Medicine</i> , 2023, 38, 375-381.	2.6	8
2	Naloxone Dispensing in Patients at Risk for Opioid Overdose After Total Knee Arthroplasty Within the Veterans Health Administration. , 2022, 39, 64-69.		1
3	Randomized Policy Evaluation of the Veterans Health Administration Stratification Tool for Opioid Risk Mitigation (STORM). <i>Journal of General Internal Medicine</i> , 2022, 37, 3746-3750.	2.6	4
4	Opioid Use and Its Relationship to Cardiovascular Disease and Brain Health: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , 2021, 144, e218-e232.	1.6	20
5	Comparison of naloxone prescribing patterns due to educational outreach conducted by full-time and part-time academic detailers at the U.S. Veterans Health Administration. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 639-646.	1.5	6
6	Opioid Discontinuation Among Patients Receiving High-Dose Long-Term Opioid Therapy in the Veterans Health Administration. <i>Journal of General Internal Medicine</i> , 2020, 35, 903-909.	2.6	10
7	Opioid Prescribing and Opioid Risk Mitigation Strategies in the Veterans Health Administration. <i>Journal of General Internal Medicine</i> , 2020, 35, 927-934.	2.6	34
8	Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. <i>BMJ, The</i> , 2020, 368, m283.	6.0	138
9	Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative. <i>Implementation Science</i> , 2020, 15, 48.	6.9	16
10	Commentary on Park et al . (2020): Buprenorphine and benzodiazepine coâ€prescribingâ€key considerations and future directions. <i>Addiction</i> , 2020, 115, 933-934.	3.3	0
11	Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 24.	2.6	24
12	Overdose Risk Associated with Opioid Use upon Hospital Discharge in Veterans Health Administration Surgical Patients. <i>Pain Medicine</i> , 2019, 20, 1020-1031.	1.9	22
13	Article Commentary: Randomized Program Evaluation of the Veterans Health Administration Stratification Tool for Opioid Risk Mitigation (STORM): A Research and Clinical Operations Partnership to Examine Effectiveness. <i>Substance Abuse</i> , 2019, 40, 14-19.	2.3	25
14	Commentary on Rege <i>et al</i> . (2018): Naloxone reports to US poison centers highlight overdose prevention opportunities. <i>Addiction</i> , 2018, 113, 2316-2317.	3.3	0
15	Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: A preliminary analysis. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, S68-S72.	1.5	48
16	Medical Providersâ€™ Knowledge and Concerns about Opioid Overdose Education and Take-Home Naloxone Rescue Kits within Veterans Affairs Health Care Medical Treatment Settings. <i>Substance Abuse</i> , 2017, 38, 135-140.	2.3	24
17	Opioid overdose education and naloxone distribution: Development of the Veterans Health Administrationâ€™s national program. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, S168-S179.e4.	1.5	70
18	Development and applications of the Veterans Health Administrationâ€™s Stratification Tool for Opioid Risk Mitigation (STORM) to improve opioid safety and prevent overdose and suicide.. <i>Psychological Services</i> , 2017, 14, 34-49.	1.5	145

#	ARTICLE	IF	CITATIONS
19	Patient perspectives on an opioid overdose education and naloxone distribution program in the U.S. Department of Veterans Affairs. <i>Substance Abuse</i> , 2016, 37, 118-126.	2.3	34
20	The Future of Social Network Analysis of Health Care System Data: Promise and Concerns. <i>Journal of General Internal Medicine</i> , 2016, 31, 142-143.	2.6	1
21	Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. <i>Implementation Science</i> , 2015, 11, 64.	6.9	28
22	Extended Release Naltrexone for Alcohol Use Disorders: Quasi-Experimental Effects on Mortality and Subsequent Detoxification Episodes. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 79-83.	2.4	5
23	If pharmacotherapies for alcohol use disorders are effective, why are they underutilised?. <i>Evidence-Based Medicine</i> , 2014, 19, 230-231.	0.6	6
24	Datapoints: False Starts in Psychotherapy for Substance Use Disorders and PTSD in the VHA. <i>Psychiatric Services</i> , 2013, 64, 722-722.	2.0	12
25	Trends in Opioid Agonist Therapy in the Veterans Health Administration: Is Supply Keeping up with Demand?. <i>American Journal of Drug and Alcohol Abuse</i> , 2013, 39, 103-107.	2.1	49
26	Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers.. <i>Psychological Services</i> , 2013, 10, 410-419.	1.5	66
27	Correlates of Specialty Substance Use Disorder Treatment Among Female Patients in the Veterans Health Administration. <i>Journal of Social Work Practice in the Addictions</i> , 2012, 12, 282-301.	0.7	13
28	Receipt of opioid agonist treatment in the Veterans Health Administration: Facility and patient factors. <i>Drug and Alcohol Dependence</i> , 2012, 122, 241-246.	3.2	54
29	Commentary on Geels <i>et al</i> . (2012): The search for G spurs questions about E. <i>Addiction</i> , 2012, 107, 528-529.	3.3	0
30	Adolescent Substance Use Groups: Antecedent and Concurrent Personality Differences in a Longitudinal Study. <i>Journal of Personality</i> , 2012, 80, 769-793.	3.2	7
31	Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them. <i>Current Psychiatry Reports</i> , 2011, 13, 374-381.	4.5	125
32	Does following research-derived practice guidelines improve opiate-dependent patients' outcomes under everyday practice conditions? Results of the Multisite Opiate Substitution Treatment study. <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 173-179.	2.8	9